Stock VERU VERU INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Veru Inc.

Equities

VERU

US92536C1036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
1.31 USD -7.75% Intraday chart for Veru Inc. -13.82% +81.94%
Apr. 15 Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating MT
Apr. 01 Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating
MT
Veru Announces Date of 2024 Annual Meeting of Shareholders
AQ
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
CI
Raymond James Starts Very With Outperform Rating, $3 Price Target
MT
Veru Reschedules Annual Meeting of Shareholders
AQ
Veru Reschedules Annual Meeting of Shareholders
AQ
Certain Options of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.
CI
Certain Common Stock of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.
CI
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
AQ
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board
CI
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
AQ
Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN
AQ
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
AQ
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss
CI
Transcript : Veru Inc., Q1 2024 Earnings Call, Feb 08, 2024
Veru Reports Fiscal 2024 First Quarter Financial Highlights
AQ
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
AQ
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study
CI
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VERU Stock
  4. News Veru Inc.